Association of CYP2C19*2/3 gene polymorphism with lung cancer in Moroccan population

被引:0
|
作者
Berradi, Hind [1 ]
Kaanane, Houda [1 ]
Hassani Idrissi, Hind [1 ]
Elkadmiri, Nadia [3 ]
Benchakroun, Nadia [2 ]
Benider, Abdellatif [2 ]
Izaabel, El Hassan [4 ]
Nadifi, Sellama [1 ]
机构
[1] Hassan II Univ Casablanca, Fac Med & Pharm, Lab Cellular & Mol Pathol, BP 9154, Casablanca, Morocco
[2] CHU Ibn Rochd, Mohamed VI Ctr Canc Treatment, Anat Pathol Serv, Casablanca, Morocco
[3] IBN ZOHR Univ, Fac Polydisciplinaire Taroudant, BP 271, Taroudant 83000, Morocco
[4] Univ Ibn Zohr, Fac Sci, Cellular Biol & Mol Genet Lab, Agadir, Morocco
来源
GENE REPORTS | 2021年 / 25卷
关键词
CYP2C19*2; Cyp2c19*3; Lung cancer; Smoking; Predisposition; POOR METABOLIZERS; INCREASED RISK; CYP2C19; 2C19;
D O I
10.1016/j.genrep.2021.101314
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: As it is the case for all kinds of cancer; lung cancer is a multifactorial disease. The interaction between both Exposures to different carcinogens and individual genetic backgrounds modulate the disease risk. Cytochrome P450 family is one of the main enzymes involved in the metabolism of these carcinogens. Therefore, polymorphisms of genes encoding for the cyp450 enzymes can be responsible for the inter-individual differences in lung cancer susceptibility. In this study, we chose to focus on the Cyp2c19, as one of the crucial cyp450 enzymes associated with metabolism of a number of drugs and xenobiotics and its association with the lung cancer risk. Methods: Peripheral blood from a total of 115 Moroccan patients diagnosed with lung cancer and 105 healthy subjects was collected. The genotyping of CYP2C19*2 and CYP2C19*3 polymorphisms was carried out using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technic. Results: We found that the frequency of both CYP2C19*2 (GA+AA) genotype and CYP2C19*A allele were significantly more frequent in lung cancer patients than that in control subjects (24.3% vs 13.3%; p = 0.04 and 14.35% vs 7.15%; p = 0.01 respectively). We also found that the CYP2C19*3 A allele was only found in lung cancer patient with a frequency of 10% (p = 0.007). Consequently, the frequency of the CYP2C19*3 (GA + AA) genotype was also significantly more prevalent in lung cancer patients than that in controls (20% vs 0.00%; p = 0.005). We also found that smoking is associated to a higher lung cancer risk in participants carrying CYP2C19*3 or CYP2C19*2 GG genotypes (p < 0.0001, OR = 26.42, 95%CI = 12.38-56.36) and (p < 0.0001, OR = 24,44, 95%CI = 11,13-53,65). While the binary logistic regression analysis demonstrates that interaction of CYP2C19*2 with smoking has no effect on the lung cancer risk, unlike the CYP2C19*3 which coexisted with smoking increases lung cancer risk even more. Conclusion: These findings indicate that the CYP2C19*2 and CYP2C19*3 polymorphisms are significantly associated with lung cancer in Moroccan population. In addition, that the coexistence of CYP2C19*3 with smoking increased lung cancer risk even more.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19☆35 and CYP2C19☆2 Alleles
    Chaudhry, Amarjit S.
    Prasad, Bhagwat
    Shirasaka, Yoshiyuki
    Fohner, Alison
    Finkelstein, David
    Fan, Yiping
    Wang, Shuoguo
    Wu, Gang
    Aklillu, Eleni
    Sim, Sarah C.
    Thummel, Kenneth E.
    Schuetz, Erin G.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (08) : 1226 - 1235
  • [42] Analysis of the CYP2C19 polymorphism in a North-eastern Thai population
    Tassaneeyakul, W
    Tawalee, A
    Tassaneeyakul, W
    Kukongviriyapan, V
    Blaisdell, J
    Goldstein, JA
    Gaysornsiri, D
    PHARMACOGENETICS, 2002, 12 (03): : 221 - 225
  • [43] Association Study of Esomeprazole Pharmacokinetics and CYP2C19 Gene Polymorphisms
    Fang, Yuan
    He, Xia
    Peng, Ai
    Yang, Yi Qi
    Xiang, Jin
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (02): : 134 - 139
  • [44] Screening for CYP2C19 Gene variants in a healthy Jordanian population
    Yasin, Salem
    Tahtamouni, Lubna
    Al-Khateeb, Rema
    Abdellatif, Reem
    Al-Mazaydeh, Zainab
    Al-Emerieen, Ala'a
    Al-Khateeb, Hakam
    Al-Hadidi, Al-Hakam
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 15 (12) : 2745 - 2750
  • [45] CYP2C19 Gene Polymorphism May Be a Risk Factor for Bronchial Asthma
    Yaroglu, Hatice Yildirim
    Calikoglu, Mukadder
    Gumus, Lulufer Tamer
    MEDICAL PRINCIPLES AND PRACTICE, 2011, 20 (01) : 39 - 42
  • [46] CYP2C19 polymorphism increases the risk of endometriosis
    Christofolini, Denise Maria
    Amaro, Aline
    Mafra, Fernanda
    Sonnewend, Amanda
    Bianco, Bianca
    Barbosa, Caio Parente
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2015, 32 (01) : 91 - 94
  • [47] Relationship of CYP2C19*2 and CYP2C19*3 Gene Polymorphism with Clopidogrel Response Variability and Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention
    Liu, Yamin
    Liu, Naifeng
    Li, Weilan
    Shao, Hua
    Zhi, Hong
    Li, Jie
    PHARMACOLOGY, 2013, 91 (3-4) : 165 - 172
  • [48] SCREENING FOR CYP2C19*2, *3 AND *4 GENE VARIANTS IN A ROMANIAN POPULATION STUDY GROUP
    Buzoianu, Anca D.
    Trifa, Adrian P.
    Popp, Radu A.
    Militaru, Mariela S.
    Militaru, Claudia F.
    Bocsan, Corina I.
    Farcas, Marius F.
    Pop, Ioan V.
    FARMACIA, 2010, 58 (06) : 806 - 817
  • [49] Association of CYP2C19*2 and*17 genetic variants with hypertension in Pakistani population
    Riaz, Sana
    Mansoor, Atika
    Siddiqi, Saima
    Tareen, Muhammad Usman
    Rubab, Sana
    Batool, Ayesha
    Anwarullah
    Sultan, Aneesa
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (04) : 851 - 855
  • [50] CYP2C19 polymorphism and risk for essential tremor
    Alonso-Navarro, H.
    Martinez, C.
    Garcia-Martin, E.
    Benito-Leon, J.
    Garcia-Ferrer, I.
    Vazquez-Torres, P.
    Puertas, I.
    Lopez-Alburquerqe, T.
    Agundez, J. A. G.
    Jimenez-Jimenez, F. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 73 - 73